
Cellavision Q2 - Mostly in line with some minor issues

Redeye's view on the Q2 report. The organic growth was decent, while the gross margin development comprised most of the deviation compared to the results. We have decreased our sales estimates slightly due to uncertainty in the Americas and decreased our gross margin assumptions for the rest of 2024 and for the following years. With these changes and balance sheet adjustments, we have slightly increased our Base case to SEK 250 (245) and fair value range of SEK 165 – 388 per share

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Cellavision Q2 - Mostly in line with some minor issues](#)